JDRF Announces Research Collaboration with Dexcom, Inc. to Develop
I love the varied ways that the JDRF supports diabetes research. Getting behind a company like DexCom and assisting them with their search for better CGM technology is forward thinking philanthropy. I can't wait to see what great devices are born from this union.
NEW YORK, April 24, 2012 - JDRF, the leading global organization focused on type 1 diabetes (T1D) research, announced today that it has partnered with Dexcom, Inc. (NASDAQ:DXCM), a San Diego, CA-based medical device company focused on developing and marketing continuous glucose monitoring (CGM) systems. The goal of the partnership is to accelerate the development of a novel wireless "smart transmitter" that would allow a CGM system to communicate directly with an artificial pancreas control device currently being used for research studies, instead of only with a CGM receiver.
JDRF will provide Dexcom up to $500,000 over 12 months in milestone-based funding to complete the development, testing, and manufacturing of a custom "smart transmitter" prototype, which will be used for studies within JDRF's Artificial Pancreas Project academic research consortium. The direct communication capability enabled by the smart transmitter will be an important feature for artificial pancreas trials in outpatient (real-world) settings, as it would eliminate the need for a trial participant to carry multiple devices all wired together while testing an artificial pancreas system's ability to manage glucose levels.
People with T1D are burdened with constantly having to determine the right amount of insulin to dose at the right time, multiple times every day. Yet even with diligent monitoring, a significant portion of the day is still spent with either high or low blood sugar, placing them at risk for devastating complications. The artificial pancreas under development will be an external device that people with T1D could use to do what their bodies cannot-automatically control their blood sugar around the clock. It will work by combining an insulin pump and a CGM, which provides glucose readings every 1-5 minutes, with sophisticated computer software that allows the two devices to "talk to each other" to determine and provide automatically the right amount of insulin at the right time. Currently, all in-hospital artificial pancreas studies use wires and cables to connect a CGM system and an insulin pump to laptop computers or smartphones, which act as the artificial pancreas controllers.
In current CGM systems, the transmitter sends real-time glucose levels from the sensor to a receiver. In comparison, Dexcom's next generation of "smart transmitters" will have the ability to wirelessly transmit a glucose value directly to multiple devices, including several versions of an artificial pancreas controller.
"This robust wireless capability could greatly enhance the performance of closed-loop algorithms in outpatient studies, and we are proud to be working with JDRF on this exciting venture," said Terrance Gregg, chief executive officer of Dexcom.
"In order for us to truly achieve real-life outpatient studies of artificial pancreas systems, we need systems that will allow people the freedom and ability to move around while also providing safety, monitoring, and data collection," said Aaron Kowalski, Ph.D., assistant vice president of treatment therapies for JDRF. "Dexcom's 'smart transmitter' will allow the sensor to talk directly to multiple artificial pancreas control devices, and essentially eliminate the hassle of being encumbered by wires and other devices while trying to be active. Now that the first outpatient studies have started, the development of robust wireless connection capability is a key step toward accelerating the delivery of an artificial pancreas to all patients with T1D."
Apidra SoloStar supply news
Looks like Sanofi will have the supply of their Apidra SoloStar pen back to normal levels in the second quarter of 2012. Sanofi has made the FDA aware of their timetable and SoloStar users should be happy again in just a short time.
The company has produced a web page that can help a SoloStar user navigate the supply issues and they've also extended their free Apidra offer as a way to help soften the sting of this inconvenience. We've taken advantage of the free offer even though Arden doesn't use the SoloStar pen... Nothing better then free insulin, right?
Arden's A1c is at it's lowest ever since we switched to Apidra so I'm more then excited and happy to let you all know that it's out there and for a while longer, free.
Manny Hernandez interviews Dr. Denise Faustman
I'm reposting, with Manny's kind permission, his tudiabetes interview with Denise L. Faustman, MD, PhD.
Dr. Faustman is the Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. - Her research regarding type I diabetes is exciting and encouraging, this interview is more then worth watching. http://www.faustmanlab.org/
Sanofi Data Design Diabetes Q&A
I was fortunate to be able to ask Michele Polz, Head of Patient Solutions for Sanofi US Diabetes a few questions about Sanofi's Data Design Diabetes Innovation Challenge. The diabetes group at Sanofi has been putting so much good stuff out into the diabetes community since they arrived. When I say 'good stuff' I mean that I've never met a group of people who aren't diabetic that are so dedicated to making a positive difference in the lives of the people who are.
The support that the DOC receives from Discuss Diabetes and Sanofi is immense and they aren't showing any signs of slowing down. I believe that the direction Sanofi has taken when it comes to creating better outcomes for patients is one of the more encouraging things that I've seen in some time. There was a time that if I saw a pharma company getting involved with patients I immediately thought, "hmm, what's their angle... what do they want?". While I can't speak to every pharma or device manufacturer out there, I can tell you that I've met the people at Sanofi and they may be the most dedicated diabetes advocates that I've ever encountered.
After you check out the Q&A take a moment to watch the video and then get your design idea entered! The prizes are substantial! 5 semi-finalists receive, $20,000 for development of the concept prototype, intensive mentorship from industry leaders to hone the concept and participation in a design boot camp. 2 finalists get $10,000 to create a community-based proof-of-concept program and the winner (1) received $100,000 to develop their solution.
1. What is Data Design Diabetes™?
Data Design Diabetes™ is a next-generation challenge that brings together the richness of open data sets, the values of human-centered design, and the leading-edge methodology of the top innovation accelerators, to find the next breakthrough to help millions of Americans living with diabetes.
2. Why is the Data Design Diabetes Innovation Challenge important to Sanofi?
Sanofi is casting a wide net to meet and help accelerate all of the incredible entrepreneurs who seek to improve diabetes care, by providing them with resources, mentorship, and direct insight from people living with diabetes. The Innovation Challenge is an innovative approach, with unique potential to foster the best solutions, while helping entrepreneurs grow scalable businesses that meaningfully impact healthcare.3. Is this year's challenge different than last year's Challenge?
Yes! To kick off this year's Data Design Diabetes Innovation Challenge and help shape the focus of the challenge, we crowdsourced feedback from people living with diabetes in the U.S. We are also adding a four-day Design & Prototyping Bootcamp where the five semi-finalists will learn about human-centered design, user experience, and rapid prototyping from industry experts. In addition, we are partnering with Startup America to connect the semi-finalists with valuable entrepreneurial resources. These new additions will help drive creative solutions to improve diabetes care, while enabling innovators to develop their concepts into businesses
4. How did you choose the theme for this year's Innovation Challenge?
The crowdsourcing phase of this year’s Innovation Challenge represents an exciting change in this year’s approach – a direct dialogue between people living with diabetes and the Innovation Challenge, to help shape the guidelines for innovators. The results are in! Respondents spoke up to ask that this year’s Innovation Challenge address the following criteria:
- Create tools to help us feel in control.
- Understand that diabetes affects families, not just individuals.
- We want to be well.
5. Why should I enter my idea to improve diabetes care?
Whether you’re a designer, a data wizard or a developer, regardless of your background and interests, the work you do on this challenge has the potential to improve the quality of life for millions of Americans. Your idea may spur new approaches that help us change the landscape of diabetes care in the U.S. We urge you to submit an idea to help people living with diabetes and their families.
6. When does the challenge officially open for submissions?
On February 23, 2012, the Innovation Challenge opened for entries. Innovators can submit their concepts now through March 23, 2012, at http://www.datadesigndiabetes.com/enter/.
2012 Data Design Diabetes Innovation Challenge from Data Design Diabetes on Vimeo.
sanofi-aventis U.S. Innovation Challenge: Data Design Diabetes from Data Design Diabetes on Vimeo.
The semi-finalist have been announced, learn more their innovation ideas at the link.
DexCom and Tandem Diabetes Care Announce CGM Development and Commercialization Agreement
Breaking diabetes tech news!
DexCom and Tandem Diabetes to develop a "CGM-enabled insulin pump"
Read the blurb and then continue to the link for the rest... New diabetes tech innovations are always good news, I can't wait to hear more about this and other collaborations.
SAN DIEGO--()--DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring systems, announced today that it has entered into a Development and Commercialization Agreement with Tandem Diabetes Care, Inc. to integrate a future generation of DexCom’s continuous glucose monitoring (CGM) technology with Tandem’s t:slim™ Insulin Delivery System, the first ever touch-screen insulin pump.
You can read the rest of the announcement at this link
Current Tandem Pump
Current DexCom Receiver